# Report death from other causes as an outcome of the prostate cancer service, split by deprivation and ethnicity

Source: https://onco.cc/ideas/idea-prostate-other-cause-mortality-as-a-reported-service-outcome/  
OnCo record `idea-prostate-other-cause-mortality-as-a-reported-service-outcome` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

When Black and white men in the United States are given the same treatment, the gap in dying of prostate cancer largely closes. The gap in dying of everything else does not. Cancer services measure the first and not the second, which means the surviving disparity is invisible to the people best placed to act on it.

## Summary

Dess and colleagues pooled three cohorts with progressively tighter control of access: a registry, an equal-access surgical system and four randomised radiotherapy trials. After inverse probability weighting, the prostate cancer-specific hazard for Black men fell from 1.30 to 1.09 in the registry, was not significantly different in the equal-access cohort, and was significantly lower in the trial cohort. Other-cause mortality remained significantly higher in two of the three cohorts, at subdistribution hazard ratios of 1.30 and 1.17.

That pattern has a direct operational meaning. A prostate cancer service that achieves equal treatment has done most of what it can about prostate cancer death and none of what it could about the larger remaining gap. The men in question are on androgen deprivation, which causes weight gain, insulin resistance, dyslipidaemia, loss of bone and muscle and, in some analyses, cardiovascular events; they are seen regularly by the cancer service for years; and their cardiovascular and metabolic risk is managed, if at all, elsewhere. The proposal is narrow and measurable: report other-cause mortality alongside cancer-specific mortality in every prostate cancer service audit, split by deprivation quintile and ethnicity, and make it the outcome against which a hormone therapy cardiometabolic clinic is judged.

What any of this means for someone treated in Britain, from the screening committee's position and the NICE appraisals to scanner and radiotherapy capacity, waiting times and how to reach a trial, is on the UK and NHS pathway page for prostate cancer.

## Fields

- Kind: Idea
- Last checked: 2026-09-25
- Also known as: other-cause mortality prostate service outcome; competing mortality prostate cancer equity
- Tags: prostate-evidence
- Hypothesis: Making other-cause mortality a reported and audited outcome of prostate cancer services, split by deprivation and ethnicity, will reveal a larger equity gap than cancer-specific mortality does and will support cardiometabolic intervention embedded in the cancer clinic that narrows it, at a cost per life-year lower than most systemic anticancer therapy in the same disease.
- Rationale: Prostate cancer has an unusual competing-risk structure: most men diagnosed with it die of something else, and androgen deprivation, the backbone of treatment, is itself a cardiometabolic intervention in the wrong direction. Dess supplies the measurement that separates the two gaps, and shows that the one cancer services already work on largely closes under equal access while the other does not. Nothing in a standard cancer audit captures this, because cancer audits are built around cancer-specific outcomes on the reasonable ground that other deaths are not the service's doing. In a disease treated for a decade with a drug that worsens metabolic health, that reasoning no longer holds.
- Proposed test: Add other-cause mortality, split by deprivation quintile and by ethnicity, to national prostate cancer audit reporting, using registry linkage to death certification, and publish it alongside cancer-specific mortality by provider. Then run a cluster-randomised trial in which intervention sites embed cardiometabolic assessment and treatment into the androgen deprivation follow-up appointment (blood pressure, lipids, HbA1c, bone density, structured exercise referral) and control sites continue usual referral to primary care, with other-cause mortality at five years as the primary endpoint and cardiovascular events at two years as the interim readout. Reporting can start immediately; the trial takes five years.
- Maturity: early-clinical
- Actor: policy

## Connected records

- ideas: [Cardiometabolic screening and treatment for survivors on long-term hormone therapy](https://onco.cc/ideas/idea-acc-cardiometabolic-clinic-hormone-therapy/), [Risk-stratified follow-up: low-risk survivors to primary care with fast re-entry](https://onco.cc/ideas/idea-acc-risk-stratified-follow-up/), [Structured exercise prescribed like a drug in all curative-intent cancer care](https://onco.cc/ideas/idea-exercise-as-adjuvant/)
- roadmaps: [Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch](https://onco.cc/roadmaps/prostate-roadmap/), [Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards](https://onco.cc/roadmaps/survivorship-roadmap/)
- cancers: [Localised prostate cancer, high and very high risk](https://onco.cc/cancers/prostate-high-risk/), [Localised prostate cancer, intermediate risk](https://onco.cc/cancers/prostate-intermediate-risk/), [Metastatic hormone-sensitive prostate cancer](https://onco.cc/cancers/prostate-mhspc/), [Non-metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-nmcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Diet, Exercise & Lifestyle](https://onco.cc/fronts/nutrition-lifestyle/), [Hormonal Therapy](https://onco.cc/fronts/hormonal/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- terms: [Androgen deprivation therapy (ADT)](https://onco.cc/terms/adt/), [Intermittent androgen deprivation (IAD)](https://onco.cc/terms/intermittent-androgen-deprivation/), [Other-cause mortality](https://onco.cc/terms/other-cause-mortality/), [Quality of life](https://onco.cc/terms/quality-of-life/)
- bottlenecks: [Fragmented care and guideline gaps](https://onco.cc/bottlenecks/b-care-fragmentation/), [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [Older and multimorbid patients are excluded and undertreated](https://onco.cc/bottlenecks/b-aging-comorbidity/), [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/), [Trials do not represent the people who get cancer](https://onco.cc/bottlenecks/b-trial-diversity/), [Weak real-world evidence and registries](https://onco.cc/bottlenecks/b-real-world-evidence/)
- key papers: [Association of Black race with prostate cancer-specific and other-cause mortality](https://onco.cc/key-papers/paper-dess-black-race-prostate-mortality-jama-oncol-2019/), [SWOG 9346: intermittent versus continuous androgen deprivation in metastatic prostate cancer](https://onco.cc/key-papers/paper-hussain-swog-9346-intermittent-androgen-deprivation-nejm-2013/), [Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction](https://onco.cc/key-papers/paper-conti-trans-ancestry-gwas-prostate-nat-genet-2021/), [Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme](https://onco.cc/key-papers/paper-langley-lancet/), [USPSTF 2018: screening for prostate cancer, recommendation statement (grade C at 55 to 69, grade D at 70 and over)](https://onco.cc/key-papers/paper-uspstf-prostate-screening-jama-2018/)

---
JSON: https://onco.cc/api/v1/entities/idea-prostate-other-cause-mortality-as-a-reported-service-outcome.json